There have been substantial reductions in under-5 childhood deaths worldwide, driven by the Millennium Development Goals, which ended in 2015 \[[@CIT0001]\]. However, the burden of stillbirths was not included in these goals and is considerable, with around 2.6 million stillbirths each year \[[@CIT0002]\], similar to the number of deaths occurring during the neonatal period (2.7 million) \[[@CIT0003]\]. Most stillbirths occur in low- and middle-income contexts, in sub-Saharan Africa (1.0 million) and South Asia (1.3 million).

Data on the causes of stillbirth are limited, and comparability of causes is challenging due to multiple classification systems \[[@CIT0004]\]. Obstetric emergencies, including antepartum hemorrhage and maternal hypertensive disorders (preeclampsia and eclampsia), are important contributors \[[@CIT0004]\]. Infection is also important, but apart from estimates for the contribution of maternal malaria, syphilis, and human immunodeficiency virus (HIV) \[[@CIT0004]\], data on infectious causes of stillbirth are sparse \[[@CIT0005]\].

Group B *Streptococcus* (GBS; *Streptococcus agalactiae*) maternal colonization of the genitourinary tract is common, occurring in approximately 10%--40% of women worldwide \[[@CIT0006], [@CIT0007]\]. Vertical transmission leads to high incidence of early onset (0--6 days of age) neonatal GBS disease (EOGBS), essentially (80%--90% of cases) manifesting within 24 hours after birth \[[@CIT0008]\]. GBS has more recently been identified as an important pathogen in neonatal disease in low-income contexts, including sub-Saharan Africa and India \[[@CIT0009], [@CIT0010]\].

In EOGBS and GBS-associated stillbirth, infection is likely due to ascending infection in utero from the maternal genitourinary tract, starting before delivery. Whole-genome sequencing studies demonstrate that GBS isolated at birth from the skin of newborns delivered by cesarean section are identical to those colonizing the mother. Furthermore, stillbirths with GBS isolated from postmortem blood culture were genetically identical to maternal GBS colonizing isolates \[[@CIT0011]\].

Understanding the contribution of GBS as a cause of stillbirth is important to design and implement preventive interventions. For EOGBS disease, 4 or more hours of intrapartum antibiotic prophylaxis, based either on maternal clinical risk factors or the presence of maternal GBS colonization from microbiological screening at 35--37 weeks' gestation, is frequently given in high-income contexts \[[@CIT0012], [@CIT0013]\]. However, this strategy is unlikely to prevent GBS-associated stillbirth occurring before labor and/or health facility attendance, where antibiotics could be administered. In contrast, maternal vaccination could protect the fetus from invasive disease in utero. A trivalent GBS polysaccharide-protein conjugate vaccine was recently evaluated in phase 2 clinical trials among pregnant women \[[@CIT0014]\].

We undertook a systematic review of the percentage of stillbirths associated with GBS worldwide as part of the total burden of GBS disease ([Figure 1](#F1){ref-type="fig"}). This article is part of a supplement estimating the burden of GBS disease in pregnant women, stillbirths, and infants, which is important in terms of public health policy \[[@CIT0015]\]. This supplement includes systematic reviews and meta-analyses, which form input parameters to estimates, partly through a compartmental model \[[@CIT0016]\]. These are reported individually according to international guidelines for improving estimation \[[@CIT0017], [@CIT0018]\]: maternal colonization \[[@CIT0006]\], maternal GBS disease \[[@CIT0019]\], preterm birth \[[@CIT0020]\], use of intrapartum antibiotic prophylaxis \[[@CIT0012]\], risk of newborn disease \[[@CIT0013]\], neonatal disease \[[@CIT0010]\], neonatal encephalopathy \[[@CIT0021]\], and impairment after neonatal disease \[[@CIT0022]\]. These are used for estimates of the burden of GBS in pregnant women, stillbirths, and infants worldwide \[[@CIT0016]\].

![Group B *Streptococcus* (GBS)--associated stillbirth in disease schema for GBS, as described by Lawn et al \[[@CIT0015]\].](cix58501){#F1}

The objectives of this review were (1) to undertake comprehensive, systematic literature reviews and meta-analyses to calculate the pooled percentage of stillbirths with evidence of GBS infection regionally and worldwide; (2) to use these data for estimates of the burden of GBS in pregnancy for women, stillbirth and infants; and (3) to evaluate gaps in the data and make recommendations to improve the data on GBS-associated stillbirth.

METHODS {#s5}
=======

This article is part of a wider study protocol entitled "Systematic estimates of the burden of GBS in pregnant women, stillbirths and infants worldwide." It was submitted for ethical approval to the London School of Hygiene & Tropical Medicine (reference number 11966). We describe the general methods elsewhere; here we give details of methods specific to GBS-associated stillbirth.

Definitions {#s6}
-----------

We used the World Health Organization definition of stillbirth---that is, birth of a fetus with no signs of life at ≥28 weeks' gestation or weighing ≥1000 g \[[@CIT0023]\]. Where gestational data were available, this was preferred as the birthweight threshold is not equivalent to 28 weeks' gestation \[[@CIT0024]\]. Confirmed cases of GBS-associated stillbirth were based on microbiological evidence of invasive GBS disease, from a normally sterile site such as fetal blood (sampled from the umbilical cord or from the heart), lung aspirate, cerebrospinal fluid, or fetal tissues. Cases where GBS was only isolated from a potentially contaminated site (eg, placenta or amniotic fluid \[other than by amniocentesis\], gastric or tracheal aspirate) were not included.

Data Searches and Inputs {#s7}
------------------------

We identified data through systematic review of the published literature and through development of an investigator group asking clinicians, researchers, and relevant professional institutions worldwide. For this report, we did systematic literature searches of Medline, Embase, and Literatura Latino-Americana e do Caribe em Ciências da Saúde from 15 March 2015 to 1 February 2017 to update a previous systematic review \[[@CIT0025]\]. We did systematic literature searches of the World Health Organization Library Information System and Scopus on 1 February 2017. We searched databases with variants of terms related to "stillbirth/fetal mortality" and "group B *Streptococcus.*" Medical subject headings (MeSH) terms were used where possible (see Supplementary Table 1 for the full list of search terms). We did not apply language or date restrictions. We used snowball searches of article reference lists to identify additional studies \[[@CIT0018]\]. Two independent investigators (A. C. S. and F. B. J.) performed the database searches, screened titles for duplicates and for eligibility, and screened abstracts to assess their suitability for inclusion, and one investigator (A. C. S.) extracted data. The data extraction from full texts was compared to a recent systematic review \[[@CIT0025]\] and, for any discrepancies, a second investigator (F. B. J.) reextracted the data.

Inclusion and Exclusion Criteria {#s8}
--------------------------------

We included studies having a defined population denominator, including all stillbirths in a facility, or occurring in a geographical location in a specified time period (Supplementary Table 2 for inclusion and exclusion criteria). We based case ascertainment on isolation of GBS identified through conventional microbiological culture. We excluded studies where only stillbirths \<28 weeks' gestation were reported (outside of the World Health Organization definition), or where cultures were only taken from potentially nonsterile or contaminated sites.

Meta-analyses {#s9}
-------------

Random-effects meta-analyses to estimate the percentage of GBS-associated stillbirth worldwide and by region were performed using the DerSimonian and Laird method \[[@CIT0026]\] for recent data (from the year 2000).

Sensitivity Analyses {#s10}
--------------------

Sensitivity analyses were done to assess (1) changes in time, and whether recent data (from 2000) differ in the percentage of GBS-associated stillbirth when studies reporting data from all years are included; and (2) changes by region and with time, and whether there was any difference in the proportion of stillbirth associated with GBS when studies from developed regions were categorized by year periods for median year of data collection.

RESULTS {#s11}
=======

Study Selection {#s12}
---------------

We identified 303 records through the systematic searches; 14 of these studies met the inclusion criteria. Six of the included studies (3 published articles \[[@CIT0027]\] and 3 unpublished or updated datasets \[[@CIT0030]\]) reported data collected from the year 2000 onward (recent data), whereas 8 studies reported data collected before 2000 ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}) \[[@CIT0031]\].

![Data search and included studies on group B *Streptococcus*--associated stillbirth.](cix58502){#F2}

###### 

Group B *Streptococcus*--Associated Stillbirth: Characteristics of Studies and Data, All Years

  Study, First Author       Country         Location            Data Collection   Year, Median   Total Births   Total Stillbirths   Total Infectious Stillbirths   Total GBS-Associated Stillbirths
  ------------------------- --------------- ------------------- ----------------- -------------- -------------- ------------------- ------------------------------ ----------------------------------
  **Hood** \[33\]           United States   New Orleans         1958--1959        1958           NA             113                 66                             11
  **Bergqvist** \[39\]      Sweden          Stockholm           1970--1975        1973           17638          117                 24                             5
  **Christensen** \[40\]    Sweden          Lund                1979--1980        1979           130            11                  2                              1
  **Ahlenius** \[32\]       Sweden          Karolinska          1987--1989        1988           10707          66                  8                              2
  **Tolockiene** \[31\]     Sweden          Lund                1985--1994        1989           4130           117                 32                             2
  **Moyo** \[34\]           Zimbabwe        Harare              1989--1991        1990           NA             66                  43                             8
  **Folgosa** \[35\]        Mozambique      Maputo              1990--1991        1990           NA             58                  41                             0
  **Maleckiene** \[37\]     Lithuania       Kaunas University   1996--1998        1997           NA             290                 21                             2
  Embleton^a^ \[30\]        England         Newcastle           1981--2005        1992           906068         179                 139                            37
  Blackwell \[29\]          United States   Detroit             2000--2002        2001           NA             44                  NA                             1
  Monari \[28\]             Italy           Modena              2005--2011        2009           NA             109                 20                             4
  Seale \[27\]              Kenya           Kilifi              2013--2014        2013           NA             149                 NA                             4
  Madhi^a^                  South Africa    Soweto              2014--2015        2014           NA             394                 NA                             16
  Menéndez \[[@CIT0041]\]   Mozambique      Maputo              2014              2014           NA             18                  NA                             3

Studies with all data collected before 2000 are noted in bold.

Abbreviations: GBS, group B *Streptococcus*; NA, not applicable.

^a^Includes unpublished and/or updated data from the investigator group.

Study Characteristics {#s13}
---------------------

The characteristics of all 14 studies are summarized in [Table 1](#T1){ref-type="table"}. All were hospital based and included microbiological confirmation of GBS from the fetus. Most (9/14 studies) were from developed countries, with 5 of 14 studies from sub-Saharan Africa. There were no studies from Asia or South America ([Figure 3](#F3){ref-type="fig"}).

![Geographic distribution of data on group B *Streptococcus* (GBS)--associated stillbirth (all years). Borders of countries/territories in map do not imply any political statement.](cix58503){#F3}

Of the 6 studies with data collection from the year 2000, 3 were from developed countries (Italy, England, and the United States) and 3 were from sub-Saharan Africa (Kenya, South Africa, and Mozambique). Study methods differed in the details of the microbiological evidence of GBS infection. In the largest study, from England \[[@CIT0030]\], cases were diagnosed based on medical case records and autopsies. In the study from Italy \[[@CIT0034]\], samples were taken from heart blood and in the study from the United States, samples were amniotic fluid taken by amniocentesis \[[@CIT0029]\]. In the most recent studies from Kenya, South Africa, and Mozambique, the fetus was sampled after delivery: blood from the cord or a lung aspirate in the study from Kenya \[[@CIT0027]\] and cord or heart-puncture blood sampling in the study from South Africa (personal communication, S. Madhi, April 2017) and the study from Mozambique examined multiple fetal organs, with GBS detection from both conventional culture and GBS polymerase chain reaction \[[@CIT0041]\].

GBS-Associated Stillbirth {#s14}
-------------------------

The number of cases included overall was small; in studies that included data since 2000, there were 65 cases of confirmed GBS-associated stillbirth, from a total denominator of 893 stillbirths ([Table 1](#T1){ref-type="table"}). The percentage of GBS-associated stillbirths varied by region, being lower in developed countries with a pooled estimate of 1% (95% confidence interval \[CI\], 0--2%) compared to 4% (95% CI, 2%--6%) in sub-Saharan Africa ([Figure 4](#F4){ref-type="fig"}). There was moderate heterogeneity between studies (*I*^2^ = 69%).

![Pooled estimates (with 95% confidence interval \[CI\]) of proportion of group B *Streptococcus* (GBS)--associated stillbirth for regions with data since 2000, split by region (5 studies, N = 89).](cix58504){#F4}

Sensitivity Analyses {#s15}
--------------------

First, when studies reporting data from all years were included, for developed countries the pooled estimate was similar at 2% (95% CI, 1%--3%) and for sub-Saharan Africa 4% (95% CI, 1%--7%) (Supplementary Figure 1). Second, when studies from developed regions were categorized by year periods for median year of data collection, the pooled estimate was higher in the earliest studies (1961--1978) with a percentage of 6% (95% CI, 3%--10%) in stillbirths. The pooled estimate was the same in studies from 1981 to 2000 at 1% (95% CI, 0--1%) and slightly higher in 2 recent studies (2000--2017) at 3% (95% CI, 1%--3%) (Supplementary Figure 2).

DISCUSSION {#s16}
==========

GBS is an important component of the worldwide burden of 2.6 million stillbirths, accounting for around 1% (95% CI, 0--2%) of stillbirths in developed countries and 4% (95% CI, 2%--6%) in sub-Saharan Africa. This burden and the opportunities for reduction are especially important in Africa, where the number of stillbirths is high (1.1 million), and approximately 4% are associated with GBS disease. In terms of the worldwide mortality burden of GBS, stillbirths may be far more important than neonatal deaths \[[@CIT0016]\].

Estimates are limited, however, by the available data. The studies have biases in terms of access to care, samples taken, case definitions, and laboratory methods. Access to care may increase or decrease the percentage of GBS-associated stillbirth, depending on whether prenatal care reduces GBS-associated stillbirth, or if hospital delivery is more likely in mothers who notice a reduction or a cessation in fetal movements. If samples are not taken systematically, with limited numbers of sample sites (such as just fetal blood) case ascertainment will be reduced, as GBS could be detected in lung aspirate or, possibly, cerebrospinal fluid. In Mozambique, the percentage of GBS-associated stillbirth was very high (17% \[95% CI, 4%--41%\]), which may be due to the high number of samples taken, increasing the probability of detecting GBS \[[@CIT0041]\]. While molecular methods which were used would be more sensitive, all of these cases also had GBS isolated on conventional culture, so this does not explain the difference.

An important gap is that, for much of the world, there are no data on GBS-associated stillbirth, and the wide confidence intervals in regions where there are datasets reflect the limited data from these areas However, the data gap is particularly critical in Asia. In South and Southeast Asia, \>1 million of the world's 2.6 million stillbirths occur and there is also uncertainty regarding the burden of infant GBS disease. This is reflected by lower prevalence of maternal GBS colonization, and possible differences in the virulence of GBS strains, with less serotype III, commonly associated highly invasive clonal complex 17, identified \[[@CIT0006]\]. However, this is less applicable to EOGBS and GBS-associated stillbirth, where there appears from limited data to be more diverse serotypes \[[@CIT0010], [@CIT0011]\]. It is thus possible that there is an unrecognized burden of GBS-associated stillbirth and EOGBS disease in the first 24 hours after birth, which has not been identified with limited data on GBS disease at, or shortly after, delivery in South and Southeast Asia where, until recently, the majority of births occurred outside of health facilities.

The limited data reflect both the worldwide lack of attention to counting stillbirths \[[@CIT0004]\], and to investigation of the causes of stillbirth, even in high-income contexts, where most data on this subject are historic. The lower prevalence of GBS-associated stillbirth reported in more recent data from developed regions is more likely to reflect changes in obstetric care, including increased fetal monitoring, where signs of fetal distress in utero would lead to prompt delivery and treatment. Historically this would have been less likely to be detected, as is likely now in low-income and some middle-income contexts, which may increase the proportion of GBS-associated stillbirth in these contexts, compared to EOGBS disease. This may account for more differences between contexts than intrapartum antibiotic prophylaxis, which would be likely to be given too late to reduce GBS-associated stillbirths.

The data gap for stillbirth is far greater than that for neonates, where investigations are more common, although still limited in low- and middle-income settings \[[@CIT0010], [@CIT0038]\]. Improving the data on GBS-associated stillbirth is critical in terms both of assessing the case for a maternal GBS vaccine and for future maternal GBS vaccine trials. Intrapartum antibiotic prophylaxis, used to reduce EOGBS disease, is unlikely to be effective for stillbirths where infection and death may occur prior to the onset of labor. Improving surveillance and research data will require standardizing sampling with consensus on the number of samples taken (and from where), as well as the use of appropriate laboratory methods, maximizing sensitivity with conventional microbiological methods and assessing the specificity of molecular methods for GBS detection in stillbirth.

CONCLUSIONS {#s17}
===========

GBS is likely an important, potentially preventable, cause of stillbirth, especially in Africa. Improving the data across geographies, particularly South and Southeast Asia, is important, as well as establishing standard investigations and case definitions for understanding the burden of disease and for future maternal GBS vaccine trials ([Table 2](#T2){ref-type="table"}).

###### 

Key Findings and Implications

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  What's new about this?\
  • These are the first pooled estimates of the percentage of group B *Streptococcus* (GBS)--associated stillbirth, suggesting that 4% of stillbirths in Africa may be associated with GBS, and 1% in developed regions.

  What was the main finding?\
  • GBS is an important contributor to stillbirth, particularly in Africa. GBS is likely to account for more deaths in utero, than after delivery.

  How can the data be improved?\
  • There is a critical need for more data; in terms of the geographies covered, particularly in South Asia, and in standardization of sampling strategies, laboratory methods, and case definitions.

  What does it mean for policy and programs?\
  • An effective GBS vaccine could prevent stillbirths, especially in low- and middle-income contexts.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Supplementary Data {#s18}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Supplementary Material
======================

###### 

Click here for additional data file.
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